Waters™

Note d'application

Tamoxifen – Isolation of Impurities, Transfer from Analytical to Prep

Waters Corporation



This is an Application Brief and does not contain a detailed Experimental section.

Abstract

This application brief highlights the Tamoxifen impurities isolation and transfer from analytical to prepusing Symmetry and SymmetryPrep Columns.

Introduction

Compound used in this study is Tamoxifen Citrate.

Experimental

HPLC Method

Columns: Symmetry C_{18} , 3.0 x 150 mm, 5 μm

(p/n:186000109)

SymmetryPrep C_{18} , 7.8 x 300 mm, 7 μm (p/n:

WAT066235)

Mobile phase: Acetonitrile/50 mM potassium phosphate buffer,


pH 3.0 40:60

Flow rate: A. 0.4 mL/min B. 5.6 mL/min

Injection volume: 5 mg/mL tamoxifen citrate

A. 15 mg B. 101 mg

Results and Discussion



Featured Products

WA31763.163, June 2003

© 2021 Waters Corporation. All Rights Reserved.